Results 111 to 120 of about 30,985 (226)

Real‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond

open access: yesInternational Journal of Cancer, Volume 159, Issue 7, Page 1780-1787, 1 October 2026.
Progression after anti‐PD‐1‐based therapy is a predominant scenario in metastatic melanoma. However, real‐world data informing treatment of metastatic melanoma in later lines remains scarce. This retrospective nationwide, population‐based cohort study shows in a real‐world setting that nivolumab plus ipilimumab can induce durable responses beyond the ...
Yago Garitaonaindia   +11 more
wiley   +1 more source

Coexisting adenomyosis in endometriosis: Similar pain and quality of life, with longer bleeding and bowel symptoms—A comparative cross‐sectional study

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 175, Issue 1, Page 164-173, October 2026.
Abstract Objective To compare pain, menstrual flow, and quality of life (QoL) between women undergoing surgery for endometriosis only compared with women with endometriosis and coexisting adenomyosis. Methods A cross‐sectional study, set in two tertiary hospitals, of reproductive‐aged women (18–50 years) with a preoperative imaging diagnosis of ...
Mariana Matzenbacher Brunoro   +5 more
wiley   +1 more source

Sono‐Anatomy and Histology of the Deep Fasciae in the Upper Limb

open access: yesJournal of Ultrasound in Medicine, Volume 45, Issue 10, Page 2119-2140, October 2026.
The deep fascia of the upper limb represents a pivotal anatomical structure essential for effective force transmission, dynamic compartmentalization and musculoskeletal stability. Its composition (rich in type I collagen fibers) enables both mechanical resilience and functional adaptability, crucial for the upper limb's complex movements.
Carmelo Pirri   +7 more
wiley   +1 more source

Provox Life HMEs for Pulmonary Rehabilitation in HME‐Naïve Laryngectomy Patients: A Randomized Controlled Trial

open access: yesLaryngoscope Investigative Otolaryngology, Volume 11, Issue 5, October 2026.
ABSTRACT Objective To evaluate whether Provox Life Heat and Moisture Exchangers (HMEs) and attachments enable HME‐naïve laryngectomized patients to establish a 24‐h HME routine, and whether the resulting effect on pulmonary symptoms is sustained over 9 months, compared with standard care. Methods In this prospective, randomized controlled trial, 79 HME‐
Rafael De Cicco   +9 more
wiley   +1 more source

Timing of Effect Onset After Restarting Anti CGRP-(Receptor)-Monoclonal Antibodies Following a Mandatory Cessation After One year of Use–A Single Center Retrospective Cohort Study

open access: yesDrug Design, Development and Therapy
Leonidas D Panos,1– 3,* Adrian Scutelnic,1,* Susan E Plüss,1 Jacqueline Bracher,1 Jean-Benoît Rossel,4 Mattia Branca,4 Franz Riederer,1 Christoph J Schankin1,5 1Department of Neurology, Inselspital, University Hospital Bern, University of
Panos LD   +7 more
doaj  

Hippo Pathway–YAP/TAZ Signaling: Molecular Mechanisms, Biological Function, Diseases, and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 10, October 2026.
The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

open access: yesThe Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy